GlycoMimetics Incorporated
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, GlycoMimetics Incorporated sits in the top decile of US sponsors by registered trial count (#934 of 15,751 sponsors by registered trial count).
GlycoMimetics Incorporated: 15 sponsored US clinical trials, none currently recruiting.
GlycoMimetics Incorporated sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 2 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage).
Top-decile sponsor footprint
GlycoMimetics Incorporated ranks in the top decile of sponsors by registered trial count (#934 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Indexed trials (enrollment closed)
15 total, page 1 of 1
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
NCT04197999
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
NCT03616470
A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.
NCT02998099
A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
NCT02871570
Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers
NCT02931214
Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)
NCT02744833
A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects
NCT02813798
Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
NCT02433158
A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects
NCT02703051
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
NCT02306291
Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects
NCT02271113
Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers
NCT02168595
A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects
NCT01941511
Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
NCT01119833
Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease
NCT00911495
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 1 |
| Phase 3 | 2 |
How the GlycoMimetics Incorporated early-phase archive is shaped
15 indexed studies, none listed as recruiting (0% open); 11 completed (73%).
Phase mix: 2 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Therapeutic area indexing for this sponsor is limited in the public registry.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.